Background Bortezomib, a boronic acid dipeptide, is a novel proteasome inhibitor that has
been shown in preclinical and phase 1 studies to have antimyeloma activity. Methods In this …

Contributing roughly half of the biosphere’s net primary production (NPP) 1 , 2 , photosynthesis
by oceanic phytoplankton is a vital link in the cycling of carbon between living and …

A large data set containing coincident in situ chlorophyll and remote sensing reflectance
measurements was used to evaluate the accuracy, precision, and suitability of a wide variety of …

Background Patients with myeloma who relapse after high-dose chemotherapy have few
therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in …

NAD(P)H:quinone oxidoreductase 1 (NQO1) is an obligate two-electron reductase that is
involved in chemoprotection and can also bioactivate certain antitumor quinones. This review …

Background High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We
studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to …

Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell
therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

Background Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation
antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with …

Despite growing attention to the role of social context in determining political participation,
the effect of the structure of social networks remains little examined. This article introduces a …

Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly
understood. Here we report the massively parallel sequencing of 38 tumour genomes and …